PRESS RELEASE |

 

The European Journal of Nutrition has published the results of the latest in-vitro and human studies with OLECOL®. OLECOL® attenuates post-prandial glucose spikes in healthy volunteers through the inhibition of sucrose hydrolysis and glucose transport by oleuropein.

 

Maastricht, The Netherlands, April 17th, 2018

 

Oleuropein is a major constituent of olive leaves, many studies have shown the beneficial effect on various factors related to diabetes and cardiovascular development. OLECOL® is standardized in oleuropein content, highly water-soluble and has already shown in two clinical studies to improve blood lipid profiles in subjects with dyslipidaemia.

The latest research on OLECOL® conducted by research of Prof. Gary Williamson from University of Leeds in collaboration with BioActor, evaluated the effect of OLECOL® on sugar digestion and absorption.

The researchers at Leeds University first conducted in-vitro experiments to study both carbohydrate digestion enzymes and sugar transporters in vitro. This research demonstrated how these mechanisms can positively modulate postprandial glucose in healthy volunteers consuming different types of carbohydrate. Subsequently, another in vitro study showed that OLECOL® inhibited intestinal maltase, human sucrase, glucose transport across Caco-2 monolayers cells, and uptake of glucose by GLUT2 in oocyte cells.

Seven cross-over controlled randomized intervention studies, were performed on young healthy volunteers.  Five minutes after either placebo or OLECOL® intake, participants were given 109g of white bread (containing 50 g of available carbohydrates). It was shown that the combined action of OLECOL® on sucrase and on glucose transport can lead to a significant decrease in peak glucose in healthy volunteers.

The multiple benefits of OLECOL® are: improvement of blood lipid control in both subjects with hypercholesterolemia and overweight, strong antioxidant proprieties and attenuation of post- prandial sugar peaks in healthy subjects.

Feel free to contact us via info@bioactor.com for more information on the possibilities OLECOL® has to offer.

Further information can be found on: www.olecol.com

 

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bio actives that address healthy living and ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

For further information, see www.bioactor.com or contact  Saskia Bell, Marketing Officer, on +31 43 711 45 55, or send a mail to: saskia.bell@bioactor.com